Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials.

Clin Cancer Res · 2022 · PMC9662930 · PMID 35247922

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a significant trendno p-value reported

During PFS analysis, a significant trend was observed as the median PFS was improved with ramucirumab versus placebo in patients with TE ascites [4.2 vs. 2.0 months (HR: 0.46, 95% CI: 0.29‒0.74)], and without TE ascites [2.7 vs. 1.5 months (HR: 0.62, 95% CI: 0.50‒0.77); P interaction = 0.4919].

also in 9,775 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.